GLP-1s After Menopause: Does Hormone Therapy Change the Results?

The short answer

In a study of postmenopausal women on semaglutide, those also using menopausal hormone therapy lost more weight on average than those who weren't. It was small and observational, so it can't prove the hormones caused the difference. A 2026 menopause-society position statement says that link should not be a reason to start hormone therapy just to lose more weight^1,2.

I would separate the perimenopause questions from the evidence in women after menopause. I want to know whether hormone therapy changes a medication decision, and whether the studies justify changing either prescription. I would ask what was measured before treating a promising association as a reason to act.

What changes after the last period

The long-running Study of Women's Health Across the Nation tracked body composition with scans rather than scales. Through the menopause transition, the rate of fat gain doubled and lean mass started falling, and both kept going until about two years after the final period. After that, the curves flattened out³.

So by the time you're a few years past menopause, you may be carrying a different body composition than the same weight carried at forty. Bone is on its own curve too, which I went through in GLP-1s and bone density.

The one study comparing HRT and no HRT

Researchers at Mayo Clinic looked back at postmenopausal women treated with semaglutide for at least three months. Sixteen were using hormone therapy and ninety weren't¹.

The difference held after the researchers adjusted for other factors, and more of the hormone therapy group reached 5% and 10% weight loss at a year. Both groups saw improvements in blood sugar, blood pressure and cholesterol markers¹.

Now the honest part. Sixteen women is a very small group. It was a look back through records, not a trial, and women who choose hormone therapy may differ in ways a chart can't capture. The authors themselves called for larger studies¹. I'd treat it as interesting, not as a reason to do anything differently.

What the menopause specialists now say

In 2026 the Spanish Menopause Society published a position statement on GLP-1-type drugs in women around and after menopause. Their read: semaglutide has the most menopause-specific evidence of these drugs, but that evidence is still limited and mostly observational. Tirzepatide looks promising but hasn't been studied specifically in menopausal women².

On hormone therapy, they were direct: the link between hormone therapy and greater weight loss is hypothesis-generating, and it should not justify starting hormone therapy only to boost weight loss. They framed these drugs as part of a broader plan that includes belly fat, muscle, fracture risk, heart health, resistance exercise and enough protein².

That's the sentence I'd want in front of me if a social media ad were telling me to add hormones to my GLP-1.

Patch, gel or pill: the absorption question

GLP-1s slow stomach emptying, and that's why oral medicines come up. I covered the published case report about oral estrogen during dose increases in my perimenopause piece, so I won't repeat it.

The newer worry is about progesterone. Many women on estrogen also take an oral progestogen to protect the lining of the uterus. A 2026 review pointed out that tirzepatide could plausibly change how those are absorbed, especially in the first weeks and after dose increases, but nobody has measured it for the progestogens used in menopause care⁴.

Zepbound and HRT: what Lilly says

The Zepbound label warns that delayed gastric emptying can affect oral medicines⁵. I would not turn that general warning or a contraceptive interaction study into proof that menopausal hormone therapy becomes ineffective. The hypothesis-generating review specifically says therapeutic progestogen outcomes remain untested⁴.

No data isn't the same as a known problem. But it does mean whoever prescribes your hormones should know the GLP-1 is coming.

Questions for whoever prescribes both

• "Do you know I'm starting a GLP-1?" If two different clinicians handle your hormones and your weight, make sure each one knows about the other.
• "Is my estrogen or progesterone a pill? Would a patch or gel make more sense while I'm titrating?"
• "If my hot flashes or bleeding change during a dose increase, who do I call?" Bleeding after menopause always deserves a call, whatever else is going on.
• "What are we doing about muscle and bone?"

Decisions about hormone therapy belong with a menopause-informed doctor who knows your history. I would want the hormone and weight-treatment teams to agree on monitoring rather than change a route or dose myself.